Immunicon Corp

Immunicon — Investor Presentation (March 2006)

27 slides from Immunicon's investor presentation, Mar 9, 2006

  1. Slide 1: Cellular Information for Better Healthcare: Management Presentation

    Slide 1: Cellular Information for Better Healthcare: Management Presentation

    Cellular Information for Better Healthcare Management Presentation March 2006

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation may contain forward-looking statements that reflect management’s current views and opinions as to the status of the Company’s products, clinical trials, regulatory approval process, product development, research programs and other future events and operat

  3. Slide 3: Immunicon Value Proposition

    Slide 3: Immunicon Value Proposition

    Immunicon Value Proposition Our products aim to improve cancer disease management Cellular analysis products/technologies address multiple disease states Strategic marketing partnership in cancer with J&J (Veridex) FDA-cleared cancer products are on the market Compelling clinical data across multipl

  4. Slide 4: CellTracks Technology

    Slide 4: CellTracks Technology

    CellTracks® Technology Sample Collection and Preservation Standardized Rare Cell Capture Enrichment Kits for Molecular Analysis Kits and Marker Reagents for Cell Analysis Count and Characterize Rare Cells Profile Kit Circulating Tumor Cell Kit CEC Kit Endothelial Cell Kit

  5. Slide 5: Circulating Tumor Cells as a "Real-Time Biopsy" Blood Test

    Slide 5: Circulating Tumor Cells as a "Real-Time Biopsy" Blood Test

    Circulating Tumor Cells as a “Real-Time Biopsy” Blood Test Circulating Tumor Cells (CTCs) and Associated Markers: Count Assess Prognosis Direct Therapy Monitor Disease Phenotype & Genotype Diagnose Specify Therapy Determine Presence Risk Assessment for Cancer Most tumors are of epithelial cell origi

  6. Slide 6: Circulating Tumor Cells Predict Survival

    Slide 6: Circulating Tumor Cells Predict Survival

    Circulating Tumor Cells Predict Survival Before initiation of therapy %Probability of Survival 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% <5 CTCs n=90 (51%) 21.9 Months Logrank p < 0.0001 10.9 Months ³5 CTCs n=87 (49%) 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 Time from Baseline (Months) NEJM 2004

  7. Slide 7: CTCs: A New Tool to Manage Metastatic Breast Cancer

    Slide 7: CTCs: A New Tool to Manage Metastatic Breast Cancer

    CTCs: A New Tool to Manage Metastatic Breast Cancer %Probability of Survival 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 1 <5 CTCs at All Time Points 83 (47%) 2 ³5 at Baseline & <5 CTC at Last Draw 38 (21%) 3 <5 at Early Draw & ³5 CTC at Last Draw 17 (10%) 4 ³5 CTCs at All Time Points 39 (22%) 1 vs.

  8. Slide 8: Cells at any time point are bad!

    Slide 8: Cells at any time point are bad!

    Cells at any time point are bad! Median Survival (months) 29 27 25 23 21 19 17 15 13 11 9 7 5 3 1 95% Upper limit Median 95% Low limit 29% 71% 61% 56% 51% 48% 45% 43% 43% 40% 36% =0 ³1 ³2 ³3 ³4 ³5 ³6 ³7 ³8 ³9 ³10 CTC / 7.5 ml blood 233 patients

  9. Slide 9: A New Standard for Cancer Disease Management

    Slide 9: A New Standard for Cancer Disease Management

    A New Standard for Cancer Disease Management Current standard: Radiologist measures changes in lesions on a CT scan to assess tumor burden increase/decrease Subjective, semi-quantitative 3-6 months Future standard: Number, protein expression, and/or gene expression of CTCs better reflects efficacy o

  10. Slide 10: CTCs Predict Outcome Earlier and Better Than Imaging

    Slide 10: CTCs Predict Outcome Earlier and Better Than Imaging

    CTCs Predict Outcome Earlier and Better Than Imaging %Probability of Survival 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% S / PR & <5 CTCs n=83 (60%) 1 vs. 2 p=0.1878 1 vs. 3 p=0.0175 1 vs. 4 p<0.0001 PRO & <5 CTCs n=20 (14%) 26.9 Months 6.4 Months 15.3 Months 19.9 Months S / PR & ³5 CTCs n=13 ( 9%)

  11. Slide 11: Significant Clinical Utility of Circulating Tumor Cells

    Slide 11: Significant Clinical Utility of Circulating Tumor Cells

    Significant Clinical Utility of Circulating Tumor Cells Early evidence of treatment failure, i.e., change therapy within weeks Predictive at any time point during treatment CTCs predict survival time in patients undergoing chemo & hormonal therapy CTCs predict survival time in non-measurable metasta

  12. Slide 12: "Real-Time Biopsy" from a Blood Sample

    Slide 12: "Real-Time Biopsy" from a Blood Sample

    “Real-Time Biopsy” from a Blood Sample Enables selection of targeted therapies Taxol Herceptin CTC Count / 7.5ml Blood 225 200 175 150 125 100 75 50 25 0 Her2 +++ Her2 ++ Her2 + Her2 - 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Time (weeks) ? 11 Int J Oncol 21: 1111-1118, 2002

  13. Slide 13: "Real-Time Biopsy" from a Blood Sample: Profile Kit

    Slide 13: "Real-Time Biopsy" from a Blood Sample: Profile Kit

    “Real-Time Biopsy” from a Blood Sample Profile Kit Gene Expression Profiling of Carcinomas Genes # CTCs Pan Cancer Colon Cancer Breast Cancer Prostate Cancer Hormone refractory Hormone sensitive 50 Normal Donors 13 Breast Cancer Patients 31 Prostate Cancer Patients 30 Colon Cancer Patients 0.0 10.0

  14. Slide 14: FISH on Rare Cells

    Slide 14: FISH on Rare Cells

    FISH on Rare Cells Chromosome 1 Chromosome 7 Chromosome 8 Leukocyte 2 x1, 2 x 7, 2 x 8 7 1 8 1 1 8 7 8 7 8 7 1 7 8 7 8 1 Tumor Cell 3 x1, 5 x 7, 4 x 8

  15. Slide 15: Current Clinical R & D Program in Cancer

    Slide 15: Current Clinical R & D Program in Cancer

    Current Clinical R & D Program in Cancer Colorectal Cancer ~400 patient labeling study enrollment completed January 2006 FDA submission year-end 2006 Prostate Cancer ~200 patient labeling study enrollment completed January 2006 FDA submission 2H 2007 Research studies CTC research, drug targets, cell

  16. Slide 16: Many Product Opportunities

    Slide 16: Many Product Opportunities

    Many Product Opportunities Follow-on applications in cancer Other settings in cancer (diagnosis, recurrence monitoring,…) RNA/DNA/protein assays Detection of tumor cells in bone marrow Detection of endothelial cells (treatment toxicity, angiogenesis,…) Pharmaceutical Services: testing services and a

  17. Slide 17: Significant Market Opportunity

    Slide 17: Significant Market Opportunity

    Significant Market Opportunity Overall U.S. Market Cancer is the second leading killer Prevalence: 9.8 million survivors Incidence: 1.37 million new diagnoses p.a. Mortality: 570,280 deaths p.a. ~86% of all cancers are carcinomas (solid tumors) CellSearch™ System is “pan-carcinoma” 16 Cancer Facts a

  18. Slide 18: Sales and Marketing Strategy

    Slide 18: Sales and Marketing Strategy

    Sales and Marketing Strategy Pathologists/laboratories Oncologists

  19. Slide 19: Strategic Alliance in Cancer with Johnson & Johnson

    Slide 19: Strategic Alliance in Cancer with Johnson & Johnson

    Strategic Alliance in Cancer with Johnson & Johnson Key elements: Immunicon develops and manufactures J&J marketing, sales and distribution Revenue shared (~30% to IMMC on reagents) Reimbursement – J&J responsibility Existing CPT codes for reimbursement exist now Clinical data correlates with patien

  20. Slide 20: System Placements, by Customer/Geography

    Slide 20: System Placements, by Customer/Geography

    System Placements, by Customer/Geography As of 12/31/05 USA EU Japan/ Asia Total Total Shipments Hospital/Institute 11 7 4 22 Reference Lab 4 0 2 6 Pharma/CRO 4 1 0 5 Veridex internal use 6.5 1 1 8.5 Third party: 33 Total Placements: 41.5

  21. Slide 21: Summary of instrument shipments and sales

    Slide 21: Summary of instrument shipments and sales

    Summary of instrument shipments and sales Quarter ended Year ended Cumulative from launch ---—December 31, 2005---— ---—December 31, 2005---— to December 31, 2005 Instrument shipments JNJ Cust. Total JNJ Cust. Total CellTracks Analyzer II 1 8 9 7 15 22 7 15 22 CellSpotter Analyzer ——— 4 3 7 14 11 25

  22. Slide 22: Comparison of Estimated Key Economics to Lab & IMMC

    Slide 22: Comparison of Estimated Key Economics to Lab & IMMC

    Comparison of Estimated Key Economics to Lab & IMMC Lab Immunicon Instrumentation $150,000 ~$127,000 CellSearch Test $175 ~$50 Medicare ~$380 reimbursement Contribution to lab ~$200 (before labor)

  23. Slide 23: Financial condition

    Slide 23: Financial condition

    Financial condition (Dollars in thousands) December 31, 2005 December 31, 2004 Cash and cash equivalents $ 44,098 $ 53,103 Long term debt, incl current portion $ 5,884 $ 5,599 Common stock, $0.001 par value 28 23 Additional paid in capital 162,630 142,670 Accumulated deficit (118,448) (91,539) Other

  24. Slide 24: Milestones Achieved

    Slide 24: Milestones Achieved

    Milestones Achieved Publication in New England Journal of Medicine Q3/04 U.S. in vitro diagnostic (IVD) launch Q3/04 New data — 2005 AACR/ASCO/Urology Q2/05 Launch CellTracks Analyzer II Q2/05 510(k) clearance of expanded data Q405 CellTracks AutoPrep Systems (42) + cell analyzers (47) 12/31/05 Tria

  25. Slide 25: Upcoming Milestones/Presentations

    Slide 25: Upcoming Milestones/Presentations

    Upcoming Milestones/Presentations Launch first CTC FISH assay (RUO launch) 2006 Colorectal cancer 510(k) 2006 Prostate cancer data/510(k) 2007 Upcoming Scientific meetings AACR April 2006 ASCO June 2006 San Antonio Breast Cancer Symposium Dec. 2006 Upcoming investor meetings S.G. Cowen March 2006 Pa

  26. Slide 26: Immunicon Value Proposition

    Slide 26: Immunicon Value Proposition

    Immunicon Value Proposition Our products aim to improve cancer disease management Cellular analysis products/technologies address multiple disease states Strategic marketing partnership in cancer with J&J (Veridex) FDA-cleared cancer products are on the market Compelling clinical data across multipl

  27. Slide 27: Contact Information

    Slide 27: Contact Information

    Contact Information 3401 Masons Mill Road, Suite 100 Huntingdon Valley, Pennsylvania 19006 phone 215.830.0777 fax 215.830.0751 www.immunicon.com

Source: SEC EDGAR · 8-K filed Mar 9, 2006

More decks from Immunicon Corp